跳转至内容
Merck
CN

920P

Trilogy®

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.24
UNSPSC Code:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


form

aqueous solution

Quality Level

packaging

pkg of 1 L ready to use (920P-09), pkg of 1 gal ready to use (920P-10), pkg of 200 mL 20x (920P-06), pkg of 200 mL ready to use (920P-05), pkg of 240 mL 100x (920P-07), pkg of 50 mL 20x (920P-04)

technique(s)

immunohistochemistry: suitable

shipped in

ambient

General description

Trilogy is the ultimate solution for your lab. Unlike other EDTA solutions, Trilogy is a near neutral pH solution, making it less harmful on tissue, while still exhibiting the strong unmasking abilities of a conventional EDTA solution. Trilogy′s revolutionary formula combines deparaffinization, rehydration, and unmasking, all in one simple step! Trilogy allows for standardization of the pretreatment procedure, which in turn leads to more consistent and reliable results.

Physical form

Solution containing pretreatment reagents

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Trilogy is a registered trademark of Merck KGaA, Darmstadt, Germany


法规信息

监管及禁止进口产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Pamungkas Bagus Satriyo et al.
Journal of clinical medicine, 8(2) (2019-01-30)
Cancer stem cells (CSCs) promote tumor progression and distant metastasis in breast cancer. Cadherin 11 (CDH11) is overexpressed in invasive breast cancer cells and implicated in distant bone metastases in several cancers. The WNT signalling pathway regulates CSC activity. Growing
Allison R Pine et al.
Cancer discovery, 10(7), 964-979 (2020-04-08)
Glioblastoma (GBM), an incurable tumor, remains difficult to model and more importantly to treat due to its genetic/epigenetic heterogeneity and plasticity across cellular states. The ability of current tumor models to recapitulate the cellular states found in primary tumors remains
Amanda Linkous et al.
Cell reports, 26(12), 3203-3211 (2019-03-21)
The prognosis of patients with glioblastoma (GBM) remains dismal, with a median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a "normal" human microenvironment and the inability of many tumor cell lines to accurately reproduce



全球贸易项目编号

货号GTIN
920P-070841683106715
920P-040841683144908
920P-060841683144922
920P-090841683106739
920P-050841683144915
920P-100841683106722